KRAS and non-small cell lung carcinoma: Effect of dacomitinib on OS was similar regardless of EGFR mutation status; however, OS results appeared to differ by KRAS mutation status, with dacomitinib improving OS in patients with KRAS wild-type tumors (7.0 vs. 5.2 months; hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.61–1.03), but worsening OS in patients with KRAS mutation-positive NSCLC (5.8 vs. 8.3 months; HR, 2.1; 95% CI, 1.05–4.22; interaction P = 0.08).